 Albert Kim
Concepts (104)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Comprehension | 6 | 2025 | 181 | 2.620 |
Why?
| | Electroencephalography | 7 | 2025 | 534 | 1.840 |
Why?
| | Evoked Potentials | 4 | 2025 | 128 | 1.790 |
Why?
| | Theta Rhythm | 2 | 2025 | 18 | 1.750 |
Why?
| | Brain Neoplasms | 9 | 2024 | 1322 | 1.500 |
Why?
| | Semantics | 5 | 2025 | 100 | 1.420 |
Why?
| | Language | 3 | 2024 | 323 | 1.010 |
Why?
| | Brain | 7 | 2025 | 2934 | 1.000 |
Why?
| | Reading | 4 | 2025 | 136 | 0.960 |
Why?
| | Executive Function | 3 | 2025 | 459 | 0.930 |
Why?
| | Cognition | 3 | 2025 | 1262 | 0.720 |
Why?
| | Evoked Potentials, Visual | 2 | 2012 | 42 | 0.710 |
Why?
| | Vocabulary | 2 | 2012 | 36 | 0.710 |
Why?
| | Meningeal Neoplasms | 4 | 2023 | 94 | 0.670 |
Why?
| | Pattern Recognition, Visual | 2 | 2012 | 105 | 0.670 |
Why?
| | Brain Mapping | 3 | 2012 | 536 | 0.630 |
Why?
| | Antibodies, Monoclonal, Humanized | 4 | 2024 | 988 | 0.630 |
Why?
| | Psycholinguistics | 2 | 2023 | 20 | 0.580 |
Why?
| | Precision Medicine | 1 | 2023 | 463 | 0.580 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2024 | 900 | 0.560 |
Why?
| | Aptitude | 1 | 2017 | 31 | 0.520 |
Why?
| | Encephalitis | 1 | 2018 | 139 | 0.480 |
Why?
| | Individuality | 1 | 2017 | 152 | 0.480 |
Why?
| | Memory, Short-Term | 1 | 2017 | 272 | 0.440 |
Why?
| | Cerebral Cortex | 1 | 2017 | 467 | 0.410 |
Why?
| | Dementia | 1 | 2018 | 299 | 0.410 |
Why?
| | Meningeal Carcinomatosis | 2 | 2021 | 7 | 0.360 |
Why?
| | Meningioma | 2 | 2023 | 87 | 0.350 |
Why?
| | Disease Progression | 2 | 2022 | 2881 | 0.340 |
Why?
| | Antineoplastic Agents, Immunological | 2 | 2024 | 199 | 0.320 |
Why?
| | Autoantibodies | 1 | 2018 | 1498 | 0.320 |
Why?
| | Glioblastoma | 2 | 2024 | 354 | 0.310 |
Why?
| | Speech Perception | 1 | 2011 | 92 | 0.300 |
Why?
| | Young Adult | 6 | 2025 | 14033 | 0.290 |
Why?
| | Adult | 9 | 2025 | 40438 | 0.240 |
Why?
| | Melanoma | 2 | 2023 | 813 | 0.230 |
Why?
| | Humans | 23 | 2025 | 144857 | 0.220 |
Why?
| | Male | 12 | 2025 | 72189 | 0.220 |
Why?
| | Ipilimumab | 2 | 2021 | 39 | 0.220 |
Why?
| | Margins of Excision | 1 | 2024 | 51 | 0.210 |
Why?
| | Isocitrate Dehydrogenase | 1 | 2024 | 70 | 0.210 |
Why?
| | Radiography, Thoracic | 1 | 2024 | 176 | 0.200 |
Why?
| | Immunotherapy | 4 | 2023 | 672 | 0.190 |
Why?
| | Tumor Microenvironment | 3 | 2022 | 743 | 0.190 |
Why?
| | Female | 11 | 2025 | 78217 | 0.190 |
Why?
| | Neovascularization, Pathologic | 1 | 2024 | 290 | 0.180 |
Why?
| | CTLA-4 Antigen | 1 | 2021 | 107 | 0.170 |
Why?
| | Photic Stimulation | 2 | 2012 | 264 | 0.160 |
Why?
| | Cyclin-Dependent Kinase 6 | 1 | 2021 | 80 | 0.160 |
Why?
| | Reaction Time | 2 | 2012 | 442 | 0.150 |
Why?
| | Subthalamic Nucleus | 1 | 2020 | 83 | 0.150 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2021 | 273 | 0.150 |
Why?
| | Prognosis | 2 | 2024 | 4253 | 0.140 |
Why?
| | Glioma | 1 | 2023 | 429 | 0.140 |
Why?
| | ELAV Proteins | 1 | 2018 | 14 | 0.140 |
Why?
| | Anti-N-Methyl-D-Aspartate Receptor Encephalitis | 1 | 2018 | 18 | 0.140 |
Why?
| | Magnetic Resonance Imaging | 4 | 2024 | 3861 | 0.130 |
Why?
| | Follow-Up Studies | 2 | 2024 | 5350 | 0.130 |
Why?
| | Deep Brain Stimulation | 1 | 2020 | 212 | 0.130 |
Why?
| | Aged | 6 | 2024 | 25822 | 0.120 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2023 | 1967 | 0.110 |
Why?
| | Adolescent | 3 | 2024 | 22396 | 0.110 |
Why?
| | Cerebral Hemorrhage | 1 | 2015 | 119 | 0.110 |
Why?
| | Parkinson Disease | 1 | 2020 | 597 | 0.100 |
Why?
| | Mutation | 1 | 2024 | 4132 | 0.100 |
Why?
| | Cerebrovascular Circulation | 1 | 2015 | 274 | 0.100 |
Why?
| | Functional Laterality | 1 | 2012 | 242 | 0.080 |
Why?
| | Universities | 1 | 2012 | 456 | 0.070 |
Why?
| | Middle Aged | 4 | 2024 | 35939 | 0.070 |
Why?
| | Survival Analysis | 2 | 2021 | 1362 | 0.070 |
Why?
| | Students | 1 | 2012 | 670 | 0.060 |
Why?
| | Aging | 1 | 2015 | 1980 | 0.050 |
Why?
| | Natural Language Processing | 1 | 2024 | 104 | 0.050 |
Why?
| | Neurosurgical Procedures | 1 | 2024 | 202 | 0.050 |
Why?
| | Telomerase | 1 | 2024 | 248 | 0.050 |
Why?
| | Anorexia | 1 | 2021 | 17 | 0.040 |
Why?
| | Hepatitis | 1 | 2021 | 44 | 0.040 |
Why?
| | Cell-Free Nucleic Acids | 1 | 2021 | 33 | 0.040 |
Why?
| | Nausea | 1 | 2021 | 112 | 0.040 |
Why?
| | Exanthema | 1 | 2021 | 84 | 0.040 |
Why?
| | Globus Pallidus | 1 | 2020 | 25 | 0.040 |
Why?
| | Time Factors | 1 | 2011 | 7107 | 0.040 |
Why?
| | Cyclin-Dependent Kinase 4 | 1 | 2021 | 90 | 0.040 |
Why?
| | Fever | 1 | 2021 | 311 | 0.040 |
Why?
| | Promoter Regions, Genetic | 1 | 2024 | 1257 | 0.040 |
Why?
| | Survival Rate | 1 | 2024 | 2051 | 0.040 |
Why?
| | Fatigue | 1 | 2021 | 361 | 0.040 |
Why?
| | Colitis | 1 | 2021 | 280 | 0.040 |
Why?
| | Piperazines | 1 | 2021 | 394 | 0.030 |
Why?
| | Interferon-gamma | 1 | 2021 | 792 | 0.030 |
Why?
| | Single-Cell Analysis | 1 | 2021 | 363 | 0.030 |
Why?
| | Pyridines | 1 | 2021 | 616 | 0.030 |
Why?
| | Retrospective Studies | 2 | 2024 | 16937 | 0.030 |
Why?
| | Cerebral Amyloid Angiopathy | 1 | 2015 | 9 | 0.030 |
Why?
| | Apolipoproteins E | 1 | 2015 | 92 | 0.030 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2021 | 1498 | 0.030 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2021 | 949 | 0.030 |
Why?
| | Positron-Emission Tomography | 1 | 2015 | 320 | 0.030 |
Why?
| | Prospective Studies | 1 | 2024 | 7947 | 0.020 |
Why?
| | Imaging, Three-Dimensional | 1 | 2015 | 586 | 0.020 |
Why?
| | Neuropsychological Tests | 1 | 2015 | 1124 | 0.020 |
Why?
| | Incidence | 1 | 2015 | 2865 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2015 | 5809 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2015 | 8185 | 0.010 |
Why?
|
|
Kim's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|